About Genetic Immunity, Inc.
Genetic Immunity is a US clinical-stage biotechnology company focusing on the discovery, development and commercialization of a new class of pDNA based immunotherapies ("Immune Therapies" or "Therapeutic Vaccines") for the treatment of chronic viral infections, cancer and allergies. Our immunetherapies are designed to intensify or boost T-cell mediated immune response to modify or control incurable diseases. We believe our products will allow people to live better, healthier and longer lives.
Our proprietary Platform Technology includes an antigen specific pDNA (plasmid DNA), a nanomedicine formulation encapsulating the pDNA and a topical administration device that targets our pDNA to dendritic cells. Our technologies support the rapid and cost-effective development of original biologic products for several indications and provides tools for the selection of an optimal treatment regime for the patient, based on his or her disease and genetic background.
Our Lead Product Candidate for the treatment of HIV, which we call "DermaVir", is a therapeutic vaccine shown to be effective in boosting immune response to kill HIV-infected cells. Our preclinical, Phase I, Phase I/II and Phase II trials have demonstrated boosting of HIV-specific T-cells and specific killing of HIV-infected cells that are not eliminated by antiretroviral drugs. DermaVir has an excellent safety profile similar to vaccines used in healthy adults and children. The goal of DermaVir is to supplement ART treatments as an add-on therapy to maintaining undetectable HIV-RNA levels, thereby achieving a remission (functional cure) in HIV-infected patients.
We also have an extensive pipeline of product candidates, a number of which have animal proof of concept. Among them "ChlamyDerm", for the treatment of Chlamydia, and "Dermall" our allergen-specific immunotherapy. ChlamyDerm has successfully decreased the amount of infected cells together with infection-associated inflammation in mice experiments. DermAll decreased the allergic symptoms by balancing allergen-specific immune response in mice studies.
Our other pipeline candidates include treatments for over twenty Cancer types.
Genetic Immunity is a privately held Delaware corporation headquartered in Baltimore, Maryland.